Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans

Canadian Journal of Clinical Pharmacology

Volumn 6, Issue 2, 1999, Pages 85-90

  McPherson, Ruth ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cholesterol; Cholesteryl ester transfer protein; Cholestyramine; Simvastatin

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; COLESTYRAMINE; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; RANDOMIZED CONTROLLED TRIAL;

EID: 0032781555     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Parkinson TM, Gunderson K, Nelson NA. Effects of colestipol (U-26,597A) a new bile acid sequestrant on serum lipids in experimental animals and in man. Atherosclerosis 1970;11:531-7.
2. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 1993;269:3015-23.
3. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
4. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression study (MARS). Ann Intern Med 1993;119:969-76.
5. Waters D, Higginson LAJ, Gladstone P, et al. Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Study (CCAIT). Circulation 1994;89:959-68.
6. Effects of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study. Lancet 1994;344:633-8.
7. Furberg CD, Byington RP, Grouse JR, Espeland MA. Pravastatin, lipids and major coronary events. Am J Cardiol 1994;73:1133-4.
8. Furberg CD, Adams AP, Applegate WB, et al. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994;90:1679-87.
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
10. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. Arch Intern Med 1991;151:43-9.
11. Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. Arch Intern Med 1993;153:1079-87.
12. Neuman MP, Neuman HR, Neuman J. Significant increase of high density lipoprotein2 cholesterol under prolonged simvastatin treatment. Atherosclerosis 1991;91:S11-9.
13. Johansson J, Molgard J, Olsson AG. Plasma high density lipoprotein particle size alteration by simvastatin treatment in patients with hypercholesterolemia. Atherosclerosis 1991;91:175-84.
14. Tall A. Plasma lipid transfer protein. Annu Rev Biochem 1995;64:235-57.
15. Atger V, Delalleramoya M, Bamberger M, et al. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or apolipoprotein AI. J Clin Invest 1995;96:2613-22.
16. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL cholesterol levels. J Clin Invest 1996;97:2917-23.
17. Hannulsela ML, Liinmaa MJ, Kesaniemi YA, Savolainen MJ. Relationship of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 1994;110:35-44.
18. Kuivenhoven JA, De Kniff P, Boer JMA, et al. Heterogeneity of the CETP gene locus: influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997;17:560-80.
19. McPherson R, Grundy SM, Guerra R, Cohen JC. Allelic variation in the gene encoding the cholesteryl ester transfer protein is associated with variation in the plasma concentrations of cholesteryl ester transfer protein but not high density lipoproteins. J Lipid Res 1996;37:1743-8.
20. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998;338:86-93.
21. Friedwald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972;18:499-502.
22. Fink PC, Romer H, Haeckel R, et al. Measurement of proteins with the Behring Nephelometer. A multicenter evaluation. J Clin Chem Clin Biochem 1989;27:261-76.
23. Marcel YL, McPherson R, Hogue M, et al. Distribution and concentration of cholesteryl ester transfer protein levels in plasma of normolipemic subjects. J Clin Invest 1990;85:10-7.
24. Simons LA. Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. Clin Cardiol 1993;16:317-22.
25. Gaw A, Packard CJ, Murray EF, et al. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb 1993;13:170-89.
26. de Graaf J, Demacker PN, Stalenhoef AF. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia. Neth J Med 1993;43:254-61.
27. McPherson R, Mann CJ, Tall AR, et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia: Relationship to CETP activity and other lipoprotein variables. Arterioscler Thromb 1991;11:797-804.
28. Ahnadi CE, Berthezene F, Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis 1993;99:219-28.
29. Guerin M, Dolphin PJ, Talussot C, Grdette J, Bethezene F, Chapman MJ. Pravastatin modulates cholesteryl ester transfer from HDL to apo B containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:1359-68.
30. Kinoshita M, Teramoto T, Shimazu N, et al. CETP is a determinant of serum LDL-cholesterol but not HDL-cholesterol in healthy Japanese. Atherosclerosis 1996;120:75-82.
31. Ito T, Nishiwaki M, Ishikawa T, Nakamura H. CETP and LCAT activites are unrelated to smoking and moderate alcohol consumption in healthy normolipemic men. Japan Circ J 1995;59:541-6.
32. Gudnason V, Thormar K, Humphries S. Interaction of the cholesteryl ester transfer protein I405V polymorphism with alcohol consumption in smoking and nonsmoking healthy men and the effect on plasma HDL cholesterol and apo AI concentration. Hum Genet 1997;51:15-21.
33. Kauma H, Savolainen MJ, Heikkila R, et al. Sex difference in the regulation of plasma high density lipoprotein cholesterol by genetic and environmental factors. Hum Genet 1996;97:156-62.
34. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 1992;90:1290-5.
35. Martin L, Connelly P, Nancoo D, et al. Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in man: Relationship to apolipoprotein E genotype. J Lipid Res 1993;34:347-446.
36. Quinet EM, Huerta P, Nancoo D, Tall AR, Marcel YL, McPherson R. Adipose tissue cholesteryl ester transfer mRNA in response to probucol: Cholesterol and species dependence. J Lipid Res 1993;34:845-52.
37. McPherson R, Lau P, Kussie P, Barrett H, Tall AR. Plasma kinetics of cholesteryl ester transfer protein in the rabbit: Effects of dietary cholesterol. Arterioscler Thromb Vasc Biol 1997;17:203-10.